Document Detail

Palivizumab in congenital heart disease: should international guidelines be revised?
MedLine Citation:
PMID:  17961086     Owner:  NLM     Status:  MEDLINE    
Palivizumab has reduced the incidence of respiratory syncytial virus hospitalization in infants and children with congenital heart disease by 45%. Although the mortality rate of children with congenital heart disease hospitalized with respiratory syncytial virus infection has declined from 37% to approximately 3% over the past 3 decades, palivizumab has not been shown to improve mortality. There has been considerable controversy over the cost-effectiveness of administering palivizumab according to international guidelines, including children with congenital heart disease. In particular, the number of children that need to be treated with palivizumab to prevent one respiratory syncytial virus hospitalization increases dramatically in children > 12 months of age. As a result, the authors recommend that countries re-examine their recommendations for providing palivizumab up to age 24 months in children with congenital heart disease.
Joseph M Geskey; Neal J Thomas; Gretchen L Brummel
Related Documents :
10472576 - Late cardiotoxicity of anthracyclines in children with acute leukemia.
19859016 - Chagas disease as a cause of symptomatic chronic myocardopathy in mexican children.
7010416 - Tracheal compression by the innominate artery in infancy and childhood.
17325556 - Long-term outcome of children receiving home parenteral nutrition: a 20-year single-cen...
21371066 - Oral health and oral motor function in children with cerebral palsy.
8721026 - Burkitt's lymphoma in 63 turkish children diagnosed over a 10 year period.
Publication Detail:
Type:  Editorial    
Journal Detail:
Title:  Expert opinion on biological therapy     Volume:  7     ISSN:  1744-7682     ISO Abbreviation:  Expert Opin Biol Ther     Publication Date:  2007 Nov 
Date Detail:
Created Date:  2007-10-26     Completed Date:  2007-11-13     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  101125414     Medline TA:  Expert Opin Biol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  1615-20     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / therapeutic use*
Antiviral Agents / therapeutic use*
Heart Defects, Congenital / drug therapy*,  virology
International Cooperation
Practice Guidelines as Topic*
Respiratory Syncytial Virus Infections / drug therapy*,  virology
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antiviral Agents; 0/palivizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Regulation of airway mucin gene expression.
Next Document:  Stem cell therapy for joint problems using the horse as a clinically relevant animal model.